ArticleJournal of molecular histology2025
TRIB1 silencing attenuates epilepsy by restoring mitochondrial homeostasis and suppressing microglia-driven neuroinflammation via MAPK pathway inhibition.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aim to explore the role of Tribbles homolog 1 (TRIB1) in epilepsy (EP), specifically its modulation of mitochondrial homeostasis and the mitogen-activated protein kinase (MAPK) pathway. Gene expression profiling, differentially expressed genes screening, functional enrichment analysis, and protein-protein interaction (PPI) network construction were conducted to identify hub genes. Lipopolysaccharide (LPS)-induced BV2 cell models and lithium-pilocarpine-induced EP rat models were established to explore the impact of TRIB1 knockdown on EP development. The severity of EP in rats was evaluated by Racine scale, hematoxylin-eosin staining, and Nissl staining. Cell dysfunction was assessed by detecting cell viability, apoptosis, and oxidative stress markers. Western blot was applied to detect proteins related to mitochondrial function, microglial activation, and the MAPK pathway. We identified 16 hub genes from PPI networks. Among them, TRIB1 was upregulated in EP rats. In EP rat models, TRIB1 knockdown reduced seizure severity, improved oxidative stress, and enhanced mitochondrial homeostasis. TRIB1 knockdown increased viability, inhibited apoptosis, and restored mitochondrial homeostasis in LPS-induced BV2 cells. Moreover, TRIB1 knockdown attenuated microglia activation and neuroinflammation both in vivo and in vitro. TRIB1 knockdown suppressed the MAPK pathway in LPS-induced BV2 cells. The activation of the MAPK pathway reversed the alleviating effect of TRIB1 silencing on LPS-induced BV2 cell and mitochondrial function, as well as microglia-induced neuroinflammation. Knockdown of TRIB1 may provide novel therapeutic strategies for managing EP by restoring mitochondrial homeostasis and inhibiting neuroinflammation driven by microglial activation via the MAPK pathway.
Indexed as
Identifiers
40908404What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.